A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Alzheimer's Disease

Alzheimer Disease Clinical Trial

Official title:

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Alzheimer's Disease

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04100889
• Other study ID #: PRG-007
• Status: Recruiting
• Start date: March 2, 2020
• Est. completion date: July 2023

Study information

• Verified date: September 2021
• Source: ProgenaBiome
• Contact: Sabine Hazan, MD
• Phone: 18053390549
• Email: drsabinehazan[@]progenabiome.com
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records regarding Alzheimer's disease.

Description:

The goal of this Research Study is to better understand how the genetic information in subject's microbiome correlates to the information provided in surveys and in medical records regarding Alzheimer's disease.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: July 2023
• Est. primary completion date: March 2023
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Signed informed consent, demonstrating that the patient understands the procedures required for the study and the purpose of the study

2. Male or female patients age 18 and older

3. Diagnosis of Alzheimer's disease or dementia by a physician

4. Mini Mental Status Exam score less than 26

Exclusion Criteria:

1. Refusal to sign informed consent form

2. Treatment with antibiotics within 2 weeks prior to screening

3. Treatment with probiotics within 2 weeks prior to screening

4. History of bariatric surgery, total colectomy with ileorectal anastomosis or proctocolectomy.

5. Postoperative stoma, ostomy, or ileoanal pouch

6. Participation in any experimental drug protocol within the past 12 weeks

7. Treatment with total parenteral nutrition

8. Any clinically significant evidence of disease that could interfere with the subject's ability to enter the trial

9. Inability to adequately communicate with the investigator or their respective designee and/or comply with the requirements of the entire study

Related Conditions & MeSH terms

• Alzheimer Disease
• Alzheimer Disease 1
• Alzheimer Disease 10
• Alzheimer Disease 11
• Alzheimer Disease 12
• Alzheimer Disease 13
• Alzheimer Disease 14
• Alzheimer Disease 15
• Alzheimer Disease 16
• Alzheimer Disease 17
• Alzheimer Disease 18
• Alzheimer Disease 19
• Alzheimer Disease 2
• Alzheimer Disease 3
• Alzheimer Disease 4
• Alzheimer Disease 5
• Alzheimer Disease 6
• Alzheimer Disease 7
• Alzheimer Disease 8
• Alzheimer Disease 9, Late-Onset
• Alzheimer Disease Focal
• Alzheimer Disease, Early Onset
• Alzheimer Disease, Late Onset

Intervention

Other:
• No Intervention
There is no intervention for this study.

Locations

Country	Name	City	State
United States	ProgenaBiome	Ventura	California

Sponsors (1)

Lead Sponsor	Collaborator
ProgenaBiome

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Correlation of Microbiome to Alzheimer's Disease via Relative Abundance Found in Microbiome Sequencing	Relative abundance of bacterial classes within taxonomic phyla and, more broadly, within their domain will be analyzed by sequencing the gut microbiome. These data will then be correlated to Alzheimer's disease state	1 year